Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease

Pediatric Nephrology

Volumn 31, Issue 4, 2016, Pages 683-687

  Tran, Cheryl L ^a   Sethi, Sanjeev ^a   Murray, David ^a   Cramer, Carl H ^a   Sas, David J ^a   Willrich, Maria ^a   Smith, Richard J ^b   Fervenza, Fernando C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alternative complement pathway; Dense deposit disease; Eculizumab; Hemodialysis; Soluble C5b 9

Indexed keywords

ALBUMIN; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5B; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; FUROSEMIDE; MENINGOCOCCUS VACCINE; METHYLPREDNISOLONE; PNEUMOCOCCUS VACCINE; PREDNISONE; PROPERDIN; BIOLOGICAL MARKER; C3 PROTEIN, HUMAN; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; CASE REPORT; DENSE DEPOSIT DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULAR DYSFUNCTION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FUNCTION; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOPSY; BLOOD; COMPLEMENT ACTIVATION; DRUG EFFECTS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; BIOPSY; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84959490254     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3306-0     Document Type: Article

References (15)

1. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Cordoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Wurzner R, Zipfel PF (2007) New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18:2447–2456
2. McCaughan JA, O’Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12:1046–1051
3. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454–464
4. De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC (2015) Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol 26:2917–2929
5. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D’Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748–756
6. Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161–1163
7. Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163–1165
8. Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT (2014) Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 29:1283–1287
9. Sanchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, Lopez-Trascasa M, Bedoya R, Rodriguez de Cordoba S, Ybot-Gonzalez P (2014) Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 29:2055–2059
10. Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Fremeaux-Bacchi V, Fakhouri F (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65:484–489
11. Berthe-Aucejo A, Sacquepee M, Fila M, Peuchmaur M, Perrier-Cornet E, Fremeaux-Bacchi V, Deschenes G (2014) Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol 2014:201568
12. Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW (2015) Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 10:1773–1782
13. Rousset-Rouviere C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M (2014) Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29:1107–1111
14. Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ (2009) Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 75:952–960
15. Inman M, Prater G, Fatima H, Wallace E (2015) Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 8:445–448